AB

Abu Bakkar Gazi

Director Director DIN 08066908
DIN 08066908 First appointment Feb 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Feb 2018
Shareholding value •••• Premium profile

About Abu Bakkar Gazi

Data last updated:

Abu Bakkar Gazi was a Director at Prospect Pharmaceuticals Private Limited (2018–2021) and Director at Spasibo Enterprise Private Limited (2018–2021). The companies operate in Pharma.

DIN 08066908
Primary Designation Director
Industry Pharma
First Appointment 10 Feb 2018

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director10 Feb 20182017₹14.78 Cr (FY 2024)Active
Spasibo Enterprise Private Limited U51909WB2018PTC228980
Director27 Nov 20182018₹7.90 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Prospect Pharmaceuticals Private Limited
Spasibo Enterprise Private Limited
Premium access

Shareholding and investment profile for Abu Bakkar Gazi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abu Bakkar Gazi

Abu Bakkar Gazi was first appointed on 10 Feb 2018 as Director at Prospect Pharmaceuticals Private Limited.

Abu Bakkar Gazi held 2 earlier board appointments: Prospect Pharmaceuticals Private Limited (Director, 10 Feb 2018 to 07 Apr 2021); Spasibo Enterprise Private Limited (Director, 27 Nov 2018 to 20 Aug 2021).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available